Sansure Biotech(SH:688289)2025-02-27 10:50Financial Performance - The total operating revenue for 2024 reached CNY 1.496 billion, representing a year-on-year increase of 48.60%[5] - The net profit attributable to the parent company was CNY 259.03 million, a decrease of 28.78% compared to the previous year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses increased by 194.13% to CNY 210.74 million[3] - The basic earnings per share decreased by 29.03% to CNY 0.44[3] - The company's total assets increased by 2.12% to CNY 8.634 billion[3] - The company reported a decrease in investment income compared to the previous year, impacting overall profit contributions[6] Product Development and Innovation - The company successfully developed a "Smart Control Platform for Infectious Diseases," integrating IoT, cloud computing, big data, and AI technologies[5] - The respiratory product revenue doubled compared to the previous year, becoming a key driver of growth[5] - The company launched dozens of innovative products across key areas such as respiratory, gene sequencing, and immunology[5] Strategic Collaborations - The company is enhancing strategic collaborations with partners like QuantuMDx and First Light to improve product matrix and commercialization efficiency[6]